MSD Animal Health Receives Positive CVMP Opinion for NOBILIS MULTRIVA™ RT+IBm+ND+Gm+REOm+EDS Vaccine for Use in Chickens

RAHWAY, N.J., March 14, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBILIS MULTRIVA™ RT+IBm+ND+Gm+REOm+EDS vaccine to be administered intramuscularly in chickens from eight weeks of age, to protect against diseases caused by avian metapneumovirus also known as Turkey Rhinotracheitis (RT) virus, Infectious Bronchitis (IB) virus, Newcastle Disease (ND) virus, Infectious Bursal disease or Gumboro (G) virus, Reovirus (REO) and Egg Drop Syndrome (EDS) virus. If the European Commission (EC) adopts this this recommendation, this would be the first vaccine of the Nobilis Multriva™ platform, an innovative, upgraded product range engineered with the needs of today’s layers and breeders in mind.

“MSD Animal Health has been committed to bringing innovations to our customers that protect against the most important viral poultry pathogens for laying and breeding chickens,” said Maxim Nakhodko, Global Poultry Business Unit Lead, MSD Animal Health. “With today’s positive opinion, the NOBILIS MULTRIVA™ RT+IBm+ND+Gm+REOm+EDS vaccine is one step closer to becoming the first 9-valent inactivated viral vaccine in Europe.”

NOBILIS MULTRIVA™ RT+IBm+ND+Gm+REOm+EDS combines proven protection with a convenient small dose volume of 0.3 ml allowing a new 2000 dose presentation, which produces less waste, reduces use of refrigerator space and optimizes the vaccination process.

Based on the CVMP’s recommendation, the EC is expected to issue a decision for marketing authorization in the European Union (EU) during the second quarter of 2024.

About MSD Animal Health

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (